Agenus Inc (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, and adoptive cell therapies, announced yesterday that it has named Dr Allison Jeynes-Ellis as its new director.
Jeynes-Ellis, MD, FFPM (UK) is a trained clinician with more than 25 years of senior leadership experience in the pharmaceutical industry. Presently, she serves as chief executive officer at Avillion LLP.
Previously, she led development at Wyeth, BMS, Novartis, and GSK and has secured numerous US and EU drug approvals.
Garo Armen, PhD, chairman and CEO of Agenus, said, 'As we advance towards becoming a commercial organisation, I am delighted to welcome Dr Jeynes-Ellis to our board. Allison brings significant global drug development and commercialisation experience, which includes executing on global registrational studies resulting in regulatory approvals in US and EU and advising on commercialisation and reimbursement strategies. We will benefit from Allison's considerable development, regulatory, and commercial expertise.'
Convergent Therapeutics names new chairman of board of directors
Ionis Pharmaceuticals names new executive vice president, chief global product strategy officer
Cardinal Health names new independent director
Micron Biomedical names new scientific advisor to CEO
MedPharm names new executive chairman
Armonica Technologies names new director
Jazz Pharmaceuticals names new executive vice president and chief financial officer
Jazz Pharmaceuticals names new executive vice president and chief financial officer
Ardigen names new chief commercial officer
AbbVie names new chief executive officer
AMO Pharma collaborates with Population Health Research Institute for tideglusib clinical trial